TransGenic Group

TransGenic Group EPS Growth

The EPS Growth of TransGenic Group (2342.T) as of Nov 11, 2026 is 92.91 %. In the previous year, EPS Growth was -26,774.22 % — a change of -100.35% (higher).

EPS Growth

92.91 %

YoY

-100.35%

Last updated:

EPS Growth of TransGenic Group is 2026 92.91 % . EPS Growth of TransGenic Group was 2025 -26,774.22 % . It decreases by -100.35% higher compared to the previous year.

The TransGenic Group EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
854.28 JPY
Jan 1, 2020
-317.94 JPY
Jan 1, 2021
228.01 JPY
Jan 1, 2022
242.66 JPY
Jan 1, 2023
-121.84 JPY
Jan 1, 2024
101.01 JPY
Jan 1, 2025
-26,774.22 JPY
Jan 1, 2026
92.91 JPY
The TransGenic Group EPS Growth history
YEAREPS GrowthYoY
92.91 %-100.35%
-26,774.22 %-26,606.78%
101.01 %-182.90%
-121.84 %-150.21%
242.66 %+6.42%
228.01 %-171.71%
-317.94 %-137.22%
854.28 %-1,201.97%
-77.52 %-117.86%
434.14 %-8,698.93%
-5.05 %-104.36%
115.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

EPS Growth of TransGenic Group is 92.91 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — TransGenic Group

All Key Metrics — TransGenic Group